多发性骨髓瘤微小残留病检测研究进展

Research progress of minimal residual disease in multiple myeloma

近年来，随着临床对多发性骨髓瘤（MM）治疗效果的提高，患者的无进展生存（PFS）和总体生存（0S）期都获得延长，大部分患者可接近或达到完全缓解（CR），但多数患者仍面临MM复发的难题。目前认为导致MM复发的主要原因是体内微小残留病（MRD）的存在。MRD是指经治疗获得CR后体内残留少量血液肿瘤细胞的状态。通过高敏感度的技术检测MM患者MRD的状态，可为MM的诊断、治疗及预后提供依据。笔者拟就MM患者的MRD检测技术及其特点，MRD检测技术以及这些技术面临的挑战和未来发展方向进行综述。

In recent years, With the improvement of outcomes for patients with multiple myeloma （MM）, the duration of progression-free survival（PFS） and overall survival （OS） were extended. Many patients achieved complete response （CR）, but most patients will inevitably replased, and due to the presence of minimal residual disease （MRD）. MRD is defined as the small number of cancer cells persisted in the patients who achieving CR after treatment. The detection of MRD in MM can provide the basis for diagnosis, treatment and prognosis of MM. In this review, we will introduce the techniques for MRD detection in patients with MM, and discuss the challenges and future opportunities for MRD testing.